Janus Henderson Group PLC Boosts Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Janus Henderson Group PLC boosted its stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 22.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 3,601,168 shares of the company’s stock after purchasing an additional 663,439 shares during the quarter. Janus Henderson Group PLC’s holdings in Eyepoint Pharmaceuticals were worth $46,419,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of EYPT. California State Teachers Retirement System boosted its stake in shares of Eyepoint Pharmaceuticals by 2,158.3% in the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after buying an additional 100,447 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Eyepoint Pharmaceuticals by 58.4% during the first quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock worth $465,000 after acquiring an additional 13,297 shares during the period. Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals during the first quarter valued at approximately $36,414,000. Renaissance Technologies LLC raised its position in Eyepoint Pharmaceuticals by 90.4% during the first quarter. Renaissance Technologies LLC now owns 117,300 shares of the company’s stock valued at $1,512,000 after acquiring an additional 55,700 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in Eyepoint Pharmaceuticals by 75.2% in the first quarter. Sei Investments Co. now owns 50,506 shares of the company’s stock valued at $651,000 after acquiring an additional 21,686 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $12.25 on Friday. The business’s 50 day moving average price is $13.18 and its 200-day moving average price is $13.89. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $9.40 and a 1 year high of $19.11. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.50 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%. On average, sell-side analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $47.00 target price for the company. Guggenheim reiterated a “buy” rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Chardan Capital raised their price target on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.75.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.